Evidence map›Paper›PMID 25093286›Full record

ArticleBiochemical pharmacology2014

Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Matthew F Lazenka, Bethany G David, Aron H Lichtman, Eric J Nestler, Dana E Selley, Laura J Sim-Selley

Open access · greenAbstract read
In one paragraph

Article in Biochemical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. ΔCannabis and cannabinoid research · 2017
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Matthew F LazenkaDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA.
Bethany G DavidDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA.
Aron H LichtmanDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA.
Eric J NestlerFishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Dana E SelleyDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA.
Laura J Sim-SelleyDepartment of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: ljsimsel@vcu.edu.
Virginia Commonwealth University · USIcahn School of Medicine at Mount Sinai · US

Funding

TRANSGENIC COREP01DA008227 · NIDA · YALE UNIVERSITY · PI NESTLER, ERIC J. · 1993 to 2018
$28.1M
TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ARON H LICHTMAN · 2014 to 2026
$13.8M
MOLECULAR STUDIES OF COCAINE ACTION IN BRAINR37DA007359 · NIDA · YALE UNIVERSITY · PI NESTLER, ERIC J. · 1996 to 2020
$6.9M
Endocannabinoid modulation of pain-depressed behaviorR01DA030404 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S, SIM-SELLEY, LAURA J · 2011 to 2020
$3.7M
Brain Cannabinoid Signaling: Selectivity and AdaptationR01DA014277 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI SIM-SELLEY, LAURA J · 2002 to 2010
$1.7M
Regulation of striatal cannabinoid CB1 receptors by DARPP32 and deltaFosB mediateF31DA030227 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI LAZENKA, MATTHEW F · 2011 to 2012
$67k
NIDA NIH HHS DA014277NIDA NIH HHS DA030404NIDA NIH HHS F31 DA030227NIDA NIH HHS F31-DA030227NIDA NIH HHS P01 DA008227NIDA NIH HHS P30 DA033934NIDA NIH HHS R01 DA014277NIDA NIH HHS R01 DA030404NIDA NIH HHS R37 DA007359NIDA NIH HHS T32 DA007027
6 · The paper itself

Abstract

Repeated Δ(9)-tetrahydrocannabinol (THC) administration produces cannabinoid type 1 receptor (CB₁R) desensitization and downregulation, as well as tolerance to its in vivo pharmacological effects. However, the magnitude of CB₁R desensitization varies by brain region, with CB₁Rs in the striatum and its output nuclei undergoing less desensitization than other regions. A growing body of data indicates that regional differences in CB₁R desensitization are produced, in part, by THC-mediated induction of the stable transcription factor, ΔFosB, and subsequent regulation of CB₁Rs. The purpose of the present study was to determine whether THC-mediated induction of ΔFosB in the striatum inhibits CB₁R desensitization in the striatum and output nuclei. This hypothesis was tested using bitransgenic mice with inducible expression of ΔFosB or ΔcJun, a dominant negative inhibitor of AP-1-mediated transcription, in specific forebrain regions. Mice were treated repeatedly with escalating doses of THC or vehicle for 6.5 days, and CB₁R-mediated G-protein activation was assessed using CP55,940-stimulated [(35)S]GTPγS autoradiography. Overexpression of ΔFosB in striatal dopamine type 1 receptor-containing (D1R) medium spiny neurons (MSNs) attenuated CB₁R desensitization in the substantia nigra, ventral tegmental area (VTA) and amygdala. Expression of ΔcJun in striatal D1R- and dopamine type 2 receptor (D2R)-containing MSNs enhanced CB₁R desensitization in the caudate-putamen and attenuated desensitization in the hippocampus and VTA. THC-mediated in vivo pharmacological effects were then assessed in ΔcJun-expressing mice. Tolerance to THC-mediated hypomotility was enhanced in ΔcJun-expressing mice. These data reveal that ΔFosB and possibly other AP-1 binding proteins regulate CB₁R signaling and adaptation in the striatum and limbic system.

Indexed as

AnimalsCannabinoid Receptor AgonistsCorpus StriatumDronabinolDrug ToleranceGenes, junGTP-Binding ProteinsLimbic SystemMaleMiceMice, TransgenicProto-Oncogene Proteins c-fosReceptor, Cannabinoid, CB1Transcription Factor AP-1Cannabinoid Receptor AgonistsDronabinolFosb protein, mouseGTP-Binding ProteinsProto-Oncogene Proteins c-fosReceptor, Cannabinoid, CB1Transcription Factor AP-1AmygdalaBasal gangliaDopamine receptorG-proteinStriatumΔ(9)-Tetrahydrocannabinol

Identifiers

PMID25093286
PMCPMC4162133
OpenAlexW2063991901

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.